GLP1R and mucositis: In contrast to these results, in another study from 2018 by Hytting-Andreasen et al. on a low dose of GLP-1 receptor agonist in treatment in the same model of mucositis [72], exendin-4 (12.5 μg subcutaneous twice daily) failed to protect against the chemotherapy-associated loss in SI weight and villus atrophy at day three (Table 1).